Oarsman Capital Inc. Sells 1,001 Shares of Pfizer Inc. (NYSE:PFE)

Oarsman Capital Inc. trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 7.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,341 shares of the biopharmaceutical company’s stock after selling 1,001 shares during the period. Oarsman Capital Inc.’s holdings in Pfizer were worth $453,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. AXS Investments LLC lifted its holdings in Pfizer by 6.3% during the second quarter. AXS Investments LLC now owns 33,954 shares of the biopharmaceutical company’s stock worth $1,245,000 after acquiring an additional 2,016 shares during the period. Bedel Financial Consulting Inc. lifted its stake in Pfizer by 5.6% in the second quarter. Bedel Financial Consulting Inc. now owns 29,739 shares of the biopharmaceutical company’s stock valued at $1,091,000 after purchasing an additional 1,571 shares during the last quarter. CORDA Investment Management LLC. increased its position in Pfizer by 1.7% in the second quarter. CORDA Investment Management LLC. now owns 690,968 shares of the biopharmaceutical company’s stock worth $25,345,000 after buying an additional 11,354 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Pfizer by 21.5% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,224,094 shares of the biopharmaceutical company’s stock valued at $44,900,000 after purchasing an additional 216,291 shares during the last quarter. Finally, Shelton Capital Management increased its stake in shares of Pfizer by 2.0% in the second quarter. Shelton Capital Management now owns 354,452 shares of the biopharmaceutical company’s stock worth $13,001,000 after purchasing an additional 6,912 shares in the last quarter. 68.05% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 0.5 %

Shares of NYSE:PFE traded up $0.15 during trading on Friday, reaching $29.92. 27,082,355 shares of the company traded hands, compared to its average volume of 31,586,170. The company has a current ratio of 2.38, a quick ratio of 2.05 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52-week low of $28.93 and a 52-week high of $54.93. The firm has a market capitalization of $168.94 billion, a price-to-earnings ratio of 16.36, a P/E/G ratio of 1.91 and a beta of 0.63. The business’s fifty day moving average is $31.97 and its 200-day moving average is $35.28.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.15. The business had revenue of $13.23 billion for the quarter, compared to analyst estimates of $13.77 billion. Pfizer had a net margin of 15.30% and a return on equity of 16.72%. As a group, analysts forecast that Pfizer Inc. will post 1.56 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 4th. Stockholders of record on Friday, November 10th will be given a $0.41 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 5.48%. Pfizer’s dividend payout ratio is currently 89.62%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. Morgan Stanley cut their price objective on shares of Pfizer from $39.00 to $37.00 and set an “equal weight” rating for the company in a report on Wednesday, November 1st. Wells Fargo & Company reduced their target price on Pfizer from $39.00 to $35.00 and set an “equal weight” rating for the company in a report on Monday, October 16th. TheStreet downgraded shares of Pfizer from a “b-” rating to a “c+” rating in a report on Monday, September 25th. StockNews.com assumed coverage on shares of Pfizer in a report on Thursday, October 5th. They set a “hold” rating on the stock. Finally, JPMorgan Chase & Co. decreased their price target on shares of Pfizer from $36.00 to $34.00 and set a “neutral” rating on the stock in a report on Monday, October 16th. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $42.50.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.